Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE A subpopulation of TNBCs exhibit a basal-like morphology with immunohistochemical positivity for cytokeratins 5/6 (CK5/6) and/or epidermal growth factor receptor (EGFR), and have a high incidence of BRCA (breast cancer susceptibility) mutations. 24004841 2013
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 GeneticVariation disease BEFREE BRCA1 and MED12 were frequently mutated in triple negative breast cancer (TNBC) patients, PIK3CA and FAT1 mutations were frequent in HR+ patients, and PIK3CA and ERBB2 mutations were frequent in HER2+ patients. 29807833 2018
Entrez Id: 1111
Gene Symbol: CHEK1
CHEK1
0.100 GeneticVariation disease BEFREE There were two confirmed partial responses in patients with triple-negative breast cancer (<i>TP53</i>-mutated) and melanoma (<i>n</i> = 1 each) and one unconfirmed partial response in a patient with cancer of unknown primary origin.<b>Conclusions:</b> Chk1 inhibition with GDC-0425 in combination with gemcitabine was tolerated with manageable bone marrow suppression. 27815358 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE The aggressiveness of triple-negative breast cancer (TNBC), which lacks estrogen receptor, progesterone receptor and epidermal growth factor receptor 2 (HER2), represents a major challenge in breast cancer. 27137755 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Two TNBC cell lines were treated with lapatinib (a dual EGFR and HER2 inhibitor), foretinib (a MET inhibitor), or a combination of the two. 30227653 2018
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE Although the study group was small, these results point to BRCA2 mutations being important in TNBC. 22666503 2012
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE Because some breast cancers with BRCA1 or BRCA2 mutations are TNBC, the suppression of PARP has attracted attention as a new treatment strategy for TNBC. 22263793 2012
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE Women with triple-negative breast cancer (TNBC) are thought to be more likely to be BRCA1/2 mutation carriers, but most national guidelines for genetic testing, including those used in Germany and Austria, do not consider receptor triple negativity. 25971625 2015
Entrez Id: 367
Gene Symbol: AR
AR
0.100 GeneticVariation disease BEFREE Further subtype analysis of TNBCs showed the highest amplification rate (42%) in the basal-like 1 subtype and the lowest amplification rate (9%) in the luminal androgen receptor subtype. 26172299 2015
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE PALB2 has been shown to be a moderate-penetrance breast cancer susceptibility gene and is involved in the same DNA damage repair pathway as BRCA1 and BRCA2; this raises the possibility that germline PALB2 mutations may be involved in the pathogenesis of TNBCs. 23824750 2014
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 GeneticVariation disease BEFREE Missense mutations tended to be associated with a better survival compared to all other types of mutations in TNBC (P = 0.093) and in HER2-positive cancers (P = 0.071). 27611952 2016
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE A BRCA mutation was detected in 44 of 190 patients with triple-negative breast cancer (23 %). 25716084 2015
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 GeneticVariation disease BEFREE The expression rate of all CAF-related proteins in stromal cells was higher in the HER-2 type and TNBC than in the luminal type (p < 0.001). 30223270 2018
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE Mutations in BRCA1 were most frequent in patients with triple-negative breast cancer (18.4%), and mutations in CHEK2 were most frequent in patients with hereditary non-triple-negative breast cancers (15.9%). 26083025 2015
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 GeneticVariation disease BEFREE Sixty-five individual TNBCs were studied by sequence analysis for HER2 (exon 18-23), EGFR (exon 18-21), KRAS (exon 2), and BRAF (exon 15) mutations. 22610646 2012
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE Therefore, we screened a group of TNBC patients (n = 30) of white European descent for mutations in BRCA2 as well as in BRCA1. 22666503 2012
Entrez Id: 207
Gene Symbol: AKT1
AKT1
0.100 GeneticVariation disease BEFREE In this study, we used the Ion Personal Genome Machine (PGM) and Ion Torrent Ampliseq Cancer panel to sequence hotspot regions from PIK3CA, AKT and PTEN genes to identify genetic mutations in 39 samples of TNBC subtype from Moroccan patients and to correlate the results with clinical-pathologic data. 30227836 2018
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE Young patients, patients with triple-negative breast cancer (TNBC), and those who harbor a deleterious mutation in BRCA1 or BRCA2 are frequently considered to be at highest risk of local failure, leading to speculation that more-aggressive surgical treatment is warranted in these patients. 26432360 2015
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE Our results demonstrate the heterogeneity of MGAs, and that MGAs associated with TNBC, but not necessarily pure MGAs, are genetically advanced, clonal, and neoplastic lesions harbouring recurrent mutations in TP53 and/or other cancer genes, supporting the notion that a subset of MGAs and AMGAs may constitute non-obligate precursors of TNBCs. 26806567 2016
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 GeneticVariation disease BEFREE Sarcosine metabolism phenotype also varied according to breast cancer subtype, with high sarcosine type the most common in HER-2, and null type the most common in TNBC (p=0.003). 24884785 2014
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers. 28929593 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE Genomic analysis of TNBC has revealed large-scale transcriptional, mutational, and copy number heterogeneity, without any frequently recurrent mutations, other than TP53. 28205193 2017
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE Mutations in BRCA1 and BRCA2 or another breast cancer gene occur in one in four African American breast cancer patients with early onset disease, family history of breast or ovarian cancer, or TNBC. 25428789 2015
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 GeneticVariation disease BEFREE Triple-negative breast cancer (TNBC; estrogen receptor-negative, progesterone receptor-negative and Her-2-negative) is often accompanied by a higher frequency of p53 gene mutations. 28693277 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE More complete sampling of EGFR mutation status in triple negative breast cancer is needed to determine the true mutation rate. 21457545 2011